Longeveron to Play Prominent Role at the World Stem Cell Summit in Miami
January 22, 2018
Longeveron LLC, regenerative medicine company, announced that it will help roll out the red carpet when investigators from around the globe converge on the company’s hometown of Miami for the 2018 World Stem Cell Summit, January 22-26 at the Hyatt Regency
NEWS PROVIDED BY
Jan. 22, 2018 10:28 ET
MIAMI, Jan. 22, 2018 /PRNewswire/ — Longeveron LLC, regenerative medicine company, announced that it will help roll out the red carpet when investigators from around the globe converge on the company’s hometown of Miami for the 2018 World Stem Cell Summit, January 22-26 at the Hyatt Regency.
Longeveron Co-Founder and Chief Science Officer Joshua M. Hare, MD, FACC, FAHA, Summit Chair and Featured Speaker, will share his expertise on the promise of stem cell therapies during multiple sessions at the Summit, starting with the “Alpha Clinic: Near and Far Horizons for Regenerative Medicine” plenary session on Tuesday, January 23rd.
The following day, Dr. Hare will join other thought leaders including Marco Pahor, MD of the University of Florida, Jeremy Walston, MD of Johns Hopkins University and Sunjay Kaushal, MD, PhD of the University of Maryland Medical Center, on a panel discussing Stem Cell Therapy and Tissue Engineered Products; a lunch symposium on Advances in Mesenchymal Stem Cell Therapy for Chronic and Life Threatening Conditions; and an interactive case study presentation addressing The Bahamas as a Model for the Ethical Advancement of Cell Based Therapies.
“I’m honored to be a part of this unique event designed to share ideas and innovations among regenerative medicine innovators from around the world,” said Dr. Hare, who is also Director of the Interdisciplinary Stem Cell Institute (ISCI) and Professor of Medicine at the University of Miami Miller School of Medicine. “The regenerative medicine field is advancing so quickly that we need a forum like this Summit to keep up to date on advances. We will be sharing progress in stem cell and other therapies that could one day make a true difference for people living with Alzheimer’s disease, aging frailty, and many other common conditions.”
Longeveron is hosting the mesenchymal stem cell therapy lunch symposium as well as the Japan Partnering lunch, also scheduled for January 24th. Innovators and industry leaders from Japan feature prominently in the Summit because of their country’s commitment to support research and innovation focused on the field of regenerative medicine.
The World Stem Cell Summit will take place in conjunction with the field’s premier industry partnering event, Phacilitate Leaders Forum, Cell & Gene Therapy World and Immuno-Oncology Frontiers World. One goal of the co-events is to gain industry backing for some of the most promising translational research findings in regenerative medicine. The combined conferences are expected to attract more than 1,200 attendees from around the world, feature more than 250 speakers, and have more than 90 hours of programming focused on the latest advances in this rapidly evolving field.
About the World Stem Cell Summit
The World Stem Cell Summit is a project of the nonprofit Regenerative Medicine Foundation. Since 2003, the Foundation has built the strongest, most comprehensive and trusted global network for Regenerative Medicine, uniting the world’s leading researchers, medical centers, universities, labs, businesses, funders, policymakers, experts in law, regulation and ethics, medical philanthropies and patient organizations. The Foundation’s mission is to accelerate regenerative medicine to improve health and deliver cures. The Foundation is committed to the ethical advancement of an innovative medicine powered by regenerative, restorative, and curative technologies. More info: http://www.worldstemcellsummit.com/agenda/
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
or Longeveron’s website www.longeveron.com
SOURCE Longeveron LLC